NCT03981731

Brief Summary

the investigator proposes to use the cardiac coherence technique coupled with a hypnosis session to improve post-operative recovery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for not_applicable breast-cancer

Timeline
Completed

Started Feb 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 11, 2019

Completed
8 months until next milestone

Study Start

First participant enrolled

February 14, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 14, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 14, 2022

Completed
Last Updated

February 5, 2026

Status Verified

February 1, 2026

Enrollment Period

1.9 years

First QC Date

June 7, 2019

Last Update Submit

February 3, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of patients who have enrolled in the pre-habilitation program

    A patient will be considered to have optimally adhered to the program if she performs at least 2/3 of the proposed cardiac coherence sessions (that represents 67% of the total number of sessions), that is, at least 14 sessions over the 7 days preceding the surgery.

    7 days

Secondary Outcomes (18)

  • The preoperative anxiety score by using the Amsterdam Preoperative Anxiety and Information Scale (APAIS)

    7 days

  • Patient's satisfaction with perioperative period by using "Evaluation of the Vecu of General Anesthesia" questionnaire (EVAN-G)

    48 hours

  • Measurement of the Postoperative Quality of Recovery (QoR)

    10 days

  • Measurement of anxiety level by using a visual analogue scale

    7 days

  • Measurement of wake-up quality by using a visual analogue scale

    1 day

  • +13 more secondary outcomes

Study Arms (1)

Cardiac coherence

EXPERIMENTAL
Other: Cardiac coherence

Interventions

An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape. 3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation. \- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape.

Cardiac coherence

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years old
  • Surgery for breast or gynaecological cancer requiring scheduled hospitalization for up to 3 days
  • Signing of informed consent before any specific procedure in the study
  • Patient affiliated to a social security system

You may not qualify if:

  • Patients undergoing outpatient surgery for their cancer will not be included
  • Natural bradycardia (50 beats per minute)
  • Patient taking β-blockers, digoxin, flecaine, isoptin, cordarone, diltiazem
  • Cardiac arrhythmias
  • Severe heart failure with ventricular ejection fraction \< 40%
  • Uncontrolled chronic pain
  • Patients whose medical or psychological conditions do not allow them to complete the study or sign the consent
  • Patient does not understand the French language
  • Deaf and/or dumb patient
  • Adult patient under guardianship or curatorship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut régional du cancer de Montpellier

Montpellier, Hérault, 34298, France

Location

Related Publications (7)

  • Pekcan M, Celebioglu B, Demir B, Saricaoglu F, Hascelik G, Yukselen MA, Basgul E, Aypar U. The effect of premedication on preoperative anxiety. Middle East J Anaesthesiol. 2005 Jun;18(2):421-33.

    PMID: 16438017BACKGROUND
  • Van den Bosch JE, Moons KG, Bonsel GJ, Kalkman CJ. Does measurement of preoperative anxiety have added value for predicting postoperative nausea and vomiting? Anesth Analg. 2005 May;100(5):1525-1532. doi: 10.1213/01.ANE.0000149325.20542.D4.

    PMID: 15845719BACKGROUND
  • Munoz HR, Dagnino JA, Rufs JA, Bugedo GJ. Benzodiazepine premedication causes hypoxemia during spinal anesthesia in geriatric patients. Reg Anesth. 1992 May-Jun;17(3):139-42.

    PMID: 1606095BACKGROUND
  • Agelink MW, Majewski TB, Andrich J, Mueck-Weymann M. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med. 2002 May;30(5):997-1006. doi: 10.1097/00003246-200205000-00008.

    PMID: 12006794BACKGROUND
  • Lepouse C, Lautner CA, Liu L, Gomis P, Leon A. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth. 2006 Jun;96(6):747-53. doi: 10.1093/bja/ael094. Epub 2006 May 2.

    PMID: 16670111BACKGROUND
  • McCraty R, Atkinson M, Tiller WA, Rein G, Watkins AD. The effects of emotions on short-term power spectrum analysis of heart rate variability. Am J Cardiol. 1995 Nov 15;76(14):1089-93. doi: 10.1016/s0002-9149(99)80309-9.

    PMID: 7484873BACKGROUND
  • Amraoui J, Leclerc G, Jarlier M, Diaz J, Guler R, Demoly C, Verin C, Rey Dit Guzer S, Chalbos P, Moussion A, Taoum C, Neron M, Philibert L. Cardiac coherence and medical hypnosis: a feasibility study of a new combined approach for managing preoperative anxiety in patients with breast or gynaecological cancer. BJA Open. 2024 Sep 24;12:100309. doi: 10.1016/j.bjao.2024.100309. eCollection 2024 Dec.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Jibba AMRAOUI, MD

    Institut régional du cancer de Montpellier

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 7, 2019

First Posted

June 11, 2019

Study Start

February 14, 2020

Primary Completion

January 14, 2022

Study Completion

January 14, 2022

Last Updated

February 5, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

All data will be available after publication of the results in peer-reviewed revues, and in national and international meetings. It includes all disidentified participants' data, the study protocol, the statistical analysis plan, the clinical study report and the analytic code. The corresponding author will provide data and datasets generated and/or analyzed during the study upon reasonable request.

Shared Documents
STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
Time Frame
Access to study data upon written detailed request sent to ICM after publication.
Access Criteria
The data shared will be limited to that required for independent mandated verification of the published results, the applicant will need authorization from ICM for personal access, and data will only be transferred after signing of a data access agreement.

Locations